 The recommended dose of MMF and Myfortic are 2gday and 1440 mgday respectively in de novo transplant recipients. In clinical practice, maintenance patients i.e. those who are more than 1 year post transplantation are often not maintained on the recommended initial see below. In studies involving patients prescribed the recommended initial daily dose, MPA exposure is highly variable: The 12 hour area under the curve AUC ranges anywhere between 15 and 115 mghL. In the first post transplant year, a 12 hour AUC of 30 -60 mghl is recommended based on studies showing an increased incidence of rejection when the AUC 30 mghl, and no additional efficacy benefit with AUC 60 mghl in cyclosporine treated patients. 